The Abbott Laboratories story

What drives the business

• Abbott combines FreeStyle Libre glucose monitoring and cardiovascular devices with laboratory diagnostics, nutrition brands including Ensure and Similac, and branded generic drugs marketed outside the United States in emerging markets.
• Its acquisition of Exact Sciences, completed on March 23, 2026 under an agreement valuing the equity at approximately $21 billion, added Cologuard, Oncotype DX, Oncodetect and Cancerguard to expand its cancer screening and diagnostic business.
• Medical devices generated $5.9 billion of Abbott’s $12.6 billion revenue in the quarter to June 2026, with comparable growth of 8.4 percent supported by electrophysiology, rhythm management, diabetes care and heart failure products.
• Diagnostics generated $3.1 billion in the quarter to June 2026, with Cologuard’s mid-teens growth from new and repeat users helping counter lower respiratory virus testing sales.
• Established Pharmaceuticals grew 8.7 percent on a comparable basis in the quarter to June 2026, while Abbott’s broad customer base spans hospitals, laboratories, distributors, government agencies and consumers without dependence on any single material customer.

What the price assumes

At $100.98, the reverse DCF implies free cash flow after stock pay grows 10.4% a year for ten years using a 10.2% discount rate.

Abbott delivered 11.2% annual growth on that measure over the last 10 years, but the TenQ check sets a 7.6% bar by slowing that record halfway toward 4%.

The implied growth therefore requires less than Abbott’s historical pace but more than the check allows, against $7.8 billion of free cash flow and $718 million of stock-based pay over the last twelve months.

Value ABT on your own assumptions

What could change the story

• Nutrition sales declined 3.6 percent on a comparable basis in the quarter to June 2026 because of lower volumes and pricing actions, leaving an obstacle to broader growth despite sequential improvement.
• Total debt of $32.6 billion against $5.6 billion of cash and short-term investments makes cash generation important, while Abbott fails TenQ’s near-term liquidity and debt-trend checks.
• Return on employed capital of 8.0% falls below TenQ’s 10.0% bar, making the returns earned from Abbott’s expanded business an important test beyond revenue growth.
• GAAP diluted earnings per share of $0.53 versus adjusted diluted earnings per share of $1.31 in the quarter to June 2026 highlight the effect of excluded charges, including a $385 million legal reserve, acquisition expenses and intangible amortization.
• In August 2026, Abbott agreed to pay approximately $670 million to resolve the Gill case and claims involving approximately 2,000 other individuals over preterm infant formulas, resolving only a portion of the litigation without admitting liability.

What to watch next

• Abbott reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, making acceleration from 4.8 percent in the quarter to June 2026 a key operating test.
• Its raised full-year 2026 adjusted diluted EPS guidance is $5.45 to $5.60, with $1.38 to $1.46 projected for the third quarter of 2026.
• Subsequent releases can show whether Cologuard retains new and repeat users, nutrition volumes recover, and Libre Duo’s CE Mark and the Amulet 360 FDA submission translate into further commercial progress.
• Free cash flow, debt balances and litigation payments will show how Abbott accommodates its expanded business and legal obligations alongside shareholder distributions.

Sources

• Abbott Laboratories's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The ABT stock report, for every figure and check